Erythropoiesis-stimulating agents: Favorable safety profile when used as indicated

Strahlentherapie und Onkologie

Volumn 184, Issue 3, 2008, Pages 121-136

  Nowrousian, Mohammad R ^a   Dunst, Jürgen ^b   Vaupel, Peter ^c  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Anemia; Erythropoiesis stimulating agents; Erythropoietin receptor; Hemoglobin; Patient survival; Tumor progression

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; ERYTHROPOIETIN; FLUOROURACIL; HEMOGLOBIN; HYDROXYUREA; IFOSFAMIDE; NIMORAZOLE; PACLITAXEL; PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTICLE; BLADDER CANCER; BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG FATALITY; DRUG SAFETY; HEAD AND NECK CARCINOMA; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFORMATION RETRIEVAL; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; NONHUMAN; SQUAMOUS CELL CARCINOMA; THROMBOEMBOLISM; TREATMENT INDICATION; TUMOR GROWTH; UTERINE CERVIX CANCER;

ADULT; ANEMIA; ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD TRANSFUSION; CLINICAL TRIALS AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; EPOETIN ALFA; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; MALE; META-ANALYSIS AS TOPIC; MICE; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; OXYGEN; PRACTICE GUIDELINES AS TOPIC; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RATS; RECEPTORS, ERYTHROPOIETIN; RISK FACTORS; SAFETY; TUMOR CELLS, CULTURED;

EID: 40549113957     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00066-008-1841-3     Document Type: Article

References (172)

1. Aapro M, Barnadas A, Leonard RC, et al. Effects of epoetin beta treatment in patients with metastatic breast cancer receiving chemotherapy. Results of the BRAVE trial. Breast Cancer Res Treat 2006;100:Suppl 1:Abstract 6095.
2. Aapro M, Coiffier B, Dunst J, et al. Effect of treatment with epoetin beta on short-term tumour progression and survival in anaemic patients with cancer: a meta-analysis. Br J Cancer 2006;95:1467-73.
3. Aapro M, Leonhard RC, Barnadas A, et al. Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline-and/or taxane-based chemotherapy: results of the breast cancer - anemia and the value of erythropoietin (BRAVE) study. J Clin Oncol 2007;26:592-8.
4. Acs G, Acs P, Beckwith SM, et al. Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res 2001;61:3561-5.
5. Acs G, Chen M, Xu X, et al. Autocrine erythropoietin signalling inhibits hypoxia-induced apoptosis in human breast carcinoma cells. Cancer Lett 2004;214:243-51.
6. Acs G, Zhang PJ, McGrath CM, et al. Hypoxia-inducible erythropoietin signalling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression. Am J Pathol 2003;162:1789-806.
7. Alter HJ, Stramer SL, Roger YD. Emerging infectious diseases that threaten the blood supply. Semin Hematol 2007;44:32-41.
8. Altes A, Remacha AF, Sarda P, et al. Frequent severe iron overload after stem cell transplantation and its possible association with invasive aspergillosis. Bone Marrow Transplant 2004;34:505-9.
9. Amato A, Pescatori M. Perioperative blood transfusion for the recurrence of colorectal cancer. Cochrane Database Syst Rev 2006;1:CD005033.
10. Armand P, Kim HT, Cutler CS, et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 2007;109:4586-8.
11. Batra S, Perelman N, Luck LR, et al. Pediatric tumor cells express erythropoietin and a functional erythropoietin receptor that promotes angiogenesis and tumour cell survival. Lab Invest 2003;83:1477-87.
12. Baust H. Erythropoietin umstritten - ein Dopingmittel für Tumorzellen zur Behandlung der tumorassoziierten Anämie von Lungenkarzinom-Patienten? Strahlenther Onkol 2007;183:587-9.
13. Belenkov AI, Shenouda G, Rizhevskaya E, et al. Erythropoietin induces cancer cell resistance to ionizing radiation and to cisplatin. Mol Cancer Ther 2004;3:1525-32.
14. Berdel WE, Oberberg D, Reufi B, et al. Studies on the role of recombinant human erythropoietin in the growth regulation of human nonhematopoietic tumor cells in vitro. Ann Hematol 1991;63:5-8.
15. Bianchi R, Gilardini A, Rodriguez-Menendez V, et al. Cisplatin-induced peripheral neuropathy: neuroprotection by erythropoietin without affecting tumour growth. Eur J Cancer 2007;43:710-7.
16. Biete SA, Calvo MFA, Clavo VB, et al. Erythropoietin in cancer treatment: considerations about Henke's article. Clin Transl Oncol 2005;7:332-5.
17. Blohmer JU, Minckwitz G von, Paepke S, et al. Sequential adjuvant chemoradiotherapy with vs. without erythropoietin for patients with high-risk cervical cancer - second analysis of a prospective, randomized, open and controlled AGO- and NOGGO-intergroup study. Proc Am Soc Clin Oncol 2002;21:206a.
18. Blumberg N, Heal JM. Erythropoietin to treat anaemia in patients with head and neck cancer. Lancet 2004;363:80-1.
19. Bohlius J, Langensiepen S, Schwarzer G, et al. Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J Natl Cancer Inst 2005;97:489-98.
20. Bohlius J, Wilson J, Seidenfeld J, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006;98:708-14.
21. Bokemeyer C, Aapro MS, Courdi A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 2007;43:258-70.
22. Bottomley SS. Secondary iron overload disorders. Semin Hematol 1998;35:77-86.
23. Brown WM, Maxwell P, Graham ANJ, et al. Erythropoietin receptor expression in non-small cell lung carcinoma: a question of antibody specificity. Stem Cells 2007;25:718-22.
24. Butt NM, Clark RE. Autografting as a risk factor for persisting iron overload in long-term survivors of acute myeloid leukaemia. Bone Marrow Transplant 2003;32:909-13.
25. Cairns RA, Hill RP. Acute hypoxia enhances spontaneous lymph node metastasis in an orthotopic murine model of human cervical carcinoma. Cancer Res 2004;64:2054-61.
26. Cairns RA, Kalliomaki T, Hill RP. Acute (cyclic) hypoxia enhances spontaneous metastasis of KHT murine tumors. Cancer Res 2001;61:8903-8.
27. Canaparo R, Casale F, Muntoni E, et al. Plasma erythropoietin concentrations in patients receiving intensive platinum or nonplatinum chemotherapy. Br J Clin Pharmacol 2000;50:146-53.
28. Caocci G, Baccoli R, Ledda A, et al. A mathematical model for the evaluation of amplitude of hemoglobin fluctuations in elderly anemic patients affected by myelodysplastic syndromes: correlation with quality of life and fatigue. Leuk Res 2007;31:249-52.
29. Carvalho G, Lefaucheur C, Cherbonnier C, et al. Chemosensitization by erythropoietin through inhibition of the NF-κB rescue pathway. Oncogene 2005;24:737-45.
30. Ceelen W, Boterberg T, Smeets P, et al. Recombinant human erythropoietin α modulates the effects of radiotherapy on colorectal cancer microvessels. Br J Cancer 2007;96:692-700.
31. Cella D, Kallich J, McDermot A, et al. The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials. Ann Oncol 2004;15:979-86.
32. Cheung W, Minton N, Gunawardena K. Pharmacokinetics and pharmacodynamics of epoetin alfa once weekly and three times weekly. Eur J Clin Pharmacol 2001;57:411-8.
33. Chiesa ME, Fink NE. Reference intervals for erythropoietin measurement by the JCL EIA assay need to be determined locally. Clin Chem Lab Med 2000;38:65-6.
34. Clavo B. Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J Clin Oncol 2007;25:1447-8.
35. Couture F, Turner AR, Melosky B, et al. Prior red blood cell transfusion in cancer patients increase the risk of subsequent transfusions with or without recombinant human erythropoietin management. Oncologist 2005;10:63-71.
36. Crawford J. Erythropoietin: high profile, high scrutiny. J Clin Oncol 2007;25:1021-3.
37. Crawford J, Cella D, Cleeland CS, et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 2002;95:888-95.
38. Daneryd P, Svanberg E, Korner U, et al. Protection of metabolic and exercise capacity in unselected weight-losing cancer patients following treatment with recombinant erythropoietin: a randomized prospective study. Cancer Res 1998;58:5374-9.
39. Della Ragione F, Cucciolla V, Borriello A, et al. Erythropoietin receptors on cancer cells: a still open question. J Clin Oncol 2007;25:1812-3.
40. Demetri GD, Kris M, Wade J, et al. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 1998;16:3412-25.
41. Dunst J. Management of anemia in patients undergoing curative radiotherapy. Erythropoietin, transfusions, or better nothing? Strahlenther Onkol 2004;180:671-81.
42. Dunst J, Molls M. Incidence and impact of anemia in radiation oncology. In: Nowrousian MR, ed. Recombinant human erythropoietin (rhEPO) in clinical oncology. Wien-New York: Springer, 2002:101-25.
43. Dunst J. Treatment of anemia with rhEPO. In: Nowrousian MR, ed. Recombinant human erythropoietin (rhEPO) in clinical oncology - scientific and clinical aspects of anemia in cancer, 2nd edn. Wien-New York: Springer, 2008:615-34.
44. Elliott S, Busse L, Bass MB, et al. Anti-Epo receptor antibodies do not predict Epo receptor expression. Blood 2006;107:1892-5.
45. Elliott S, Busse L, Spahr C, et al. Anti-EpoR antibodies detect a 59-kDa EpoR protein. Blood 2006;108:1108-9.
46. EORTC Guidelines. Erythropoiesis-stimulating agents - ESAs: the 2007 position of the EORTC Working Party. Brussels: EORTC, 2007 (http://www. cancerworld.org/CancerWorld/eventDetail.aspx?id_sito=1&id_stato=1&id= 1795).
47. Eschbach JW, Adamson JW. Iron overload in renal failure patients: changes since the introduction of erythropoietin therapy. Kidney Int Suppl 1999;69:S35-43.
48. Farrell F, Lee A. The erythropoietin receptor and its expression in tumor cells and other tissues. Oncologist 2004;9:Suppl 5:18-30.
49. Fink M. FDA-Berater empfehlen restriktiven Einsatz bei Tumorpatienten: Erythropoetin in Turbulenzen. Strahlenther Onkol 2007;183:470.
50. Fishbane S, Nissenson AR. The new FDA label for erythropoietin treatment: how does it affect hemoglobin target? Kidney Int 2007;72:806-13.
51. Freidlin B, Korn EL. Erythropoietin to treat anaemia in patients with head and neck cancer. Lancet 2004;363:81.
52. Fujisaka Y, Tamura T, Ohe Y, et al. Pharmacokinetics and pharmacodynamics of weekly epoetin beta in lung cancer patients. Jpn J Clin Oncol 2006;36:477-82.
53. Gemici C. Erythropoietin to treat anaemia in patients with head and neck cancer. Lancet 2004;363:992-3.
54. Gewirtz DA, Xu D, Teneille DW, et al. Erythropoietin fails to interfere with the antiproliferative and cytotoxic effects of antitumor drugs. Clin Cancer Res 2006;12:2232-8.
55. Glaspy J, Dunst J. Can erythropoietin therapy improve survival? Oncology 2004;67:5-11.
56. Glaspy J, Smith RE, Aapro MS, et al. Results from a phase III, multicenter, randomized, double-blind, placebo-controlled study of darbepoetin alfa for the treatment of anemia in patients not receiving chemotherapy or radiotherapy. In: American Association for Cancer Research Annual Meeting: proceedings 2007, Apr 14-18; Los Angeles, CA. Philadelphia: AACR, 2007:Abstract LB3.
57. Gleeson C, Spencer D. Blood transfusion and its benefits in palliative care. Palliat Med 1995;9:307-13.
58. Golab J, Olszewska D, Mróz P, et al. Erythropoietin restores the antitumor effectiveness of photodynamic therapy in mice with chemotherapy-induced anemia. Clin Cancer Res 2002;8:1265-70.
59. González-Barón M, Ordónez A, Ranquesa R, et al. Response predicting factors to recombinant human erythropoietin in cancer patients undergoing platinum-based chemotherapy. Cancer 2002;95:2408-13.
60. Goodnough LT. Risks of blood transfusion. Anesthesiol Clin North Am 2005;23:241-52.
61. Grau C, Overgaard J. Significance of hemoglobin concentration for treatment outcome. In: Molls M, Vaupel P, eds. Blood perfusion and microenvironment of human tumors. Berlin-Heidelberg-New York: Springer, 2000: 101-12.
62. Grote T, Yeilding AL, Castillo R, et al. Efficacy and safety analysis of epoetin alfa in patients with small-cell lung cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2005;23:9377-86.
63. Haddad R, Posner M. Erythropoietin to treat anaemia in patients with head and neck cancer. Lancet 2004;363:79-80.
64. Hardee ME, Arcasoy MO, Blackwell KL, et al. Erythropoietin biology in cancer. Clin Cancer Res 2006;12:332-9.
65. Hardee ME, Cao Y, Ping F, et al. Erythropoietin blockade inhibits the induction of tumor angiogenesis and progression. PLoS ONE 2007;2:e549.
66. Hardee ME, Rabbani ZN, Arcasoy MO, et al. Erythropoietin inhibits apoptosis in breast cancer cells via an Akt-dependent pathway without modulating in vivo chemosensitivity. Mol Cancer Ther 2006;5:356-61.
67. Haroon ZA, Amin K, Jiang X, et al. A novel role for erythropoietin during fibrin-induced wound-healing response. Am J Pathol 2003;163:993-1000.
68. Harrison L, Blackwell K. Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy? Oncologist 2004;9:31-40.
69. Harrison LB, Chadha M, Hill RJ, et al. Impact of tumor hypoxia and anemia on radiation therapy outcomes. Oncologist 2002;7:492-508.
70. Hasegawa I, Tanaka K. Serum erythropoietin levels in gynecologic cancer patients during cisplatin combination chemotherapy. Gynecol Oncol 1992;46:65-8.
71. Haugen H, Magnusson B, Svensson M, et al. Preradiotherapy hemoglobin level but not microvessel density predicts locoregional control and survival in laryngeal cancer treated with primary radical radiotherapy. Clin Cancer Res 2004;10:7941-9.
72. Hebert PC, Tinmouth A, Corwin HL. Controversies in RBC transfusion in the critically ill. Chest 2007;131:1583-90.
73. Hedenus M, Vansteenkiste J, Kotasek D, et al. Darbepoetin alfa for the treatment of chemotherapy-induced anemia: disease progression and survival analysis from four randomized, double-blind, placebo-controlled trials. J Clin Oncol 2005;23:6941-8.
74. Henke M, Laszig R, Rübe C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255-60.
75. Henke M, Mattern D, Pepe M, et al. Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J Clin Oncol 2006;24:4708-13.
76. Högman CF, Meryman HT. Red blood cells intended for transfusion: quality criteria revisited. Transfusion 2006;46:137-42.
77. Hu K, Harrison LB. Impact of anemia in patients with head and neck cancer treated with radiation therapy. Curr Treat Options Oncol 2005;6:31-45.
78. Jacob JK, Barrett-Lee P. When to use red blood cell transfusions in cancer patients with solid tumors? In: Nowrousian MR, ed. Recombinant human erythropoietin (rhEPO) in clinical oncology - scientific and clinical aspects of anemia in cancer, 2nd edn. Wien-New York: Springer, 2008:393-405.
79. Jacobsen PB, Garland LL, Booth-Jones M, et al. Relationship of hemoglobin levels to fatigue and cognitive functioning among cancer patients receiving chemotherapy. J Pain Symptom Manage 2004;28:7-18.
80. Janecka IP. Erythropoietin to treat anaemia in patients with head and neck cancer. Lancet 2004;363:993-4.
81. Jelkmann W. Pharmacology, pharmacokinetics and safety of recombinant human erythropoietin (rhEPO). In: Nowrousian MR, ed. Recombinant human erythropoietin (rhEPO) in clinical oncology. Wien-New York: Springer, 2002:203-21.
82. Jelkmann W. Verschlechtert die Gabe von rekombinantem humanen Erythropoietin die Prognose von Patienten mit Kopf-Hals-Tumoren unter Radiotherapie? Strahlenther Onkol 2004;180:179-80.
83. Jelkmann W, Laugsch M. Problems in identifying functional erythropoietin receptors in cancer tissue. J Clin Oncol 2007;25:1627-34.
84. Kaanders JH, van der Kogel AJ. Erythropoietin to treat anaemia in patients with head and neck cancer. Lancet 2004;363:78-9.
85. Kaltwasser JP, Gottschalk R. Erythropoietin and iron. Kidney Int Suppl 1999;69:S49-56.
86. Kapp KS, Poschauko J, Geyer E, et al. Evaluation of the effect of routine packed red blood cell transfusion in anemic cervix cancer patients treated with radical radiotherapy. Int J Radiat Oncol Biol Phys 2002;54:58-66.
87. Katz O, Barzilay E, Skaat A et al. Erythropoietin induced tumour mass reduction in murine lymphoproliferative models. Acta Haematol 2005;114:177-9.
88. Kirkpatrick JP, Hardee ME, Snyder SA, et al. The effect of darbepoetin alpha on growth, oxygenation and radioresponsiveness of a breast adenocarcinoma. Radiat Res 2006;165:192-201.
89. Klein HG, Spahn DR, Carson JL. Red blood cell transfusion in clinical practice. Lancet 2007;370:415-26.
90. Kokhaei P, Abdalla AO, Hansson L, et al. Expression of erythropoietin receptor and in vitro functional effects of epoetins in B-cell malignancies. Clin Cancer Res 2007;13:3536-44.
91. Kumar SM, Acs G, Fang D, et al. Functional erythropoietin autocrine loop in melanoma. Am J Pathol 2005;166:823-30.
92. LaMontagne KR, Butler J, Marshall DJ, et al. Recombinant epoetins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models. Mol Cancer Ther 2006;5:347-55.
93. Larsson AM, Landberg G, Pahlman S, et al. Erythropoietin enhances response to treatment in patients with advanced breast cancer. Acta Oncol 2004;43:594-7.
94. Laugsch M, Metzen E, Svensson T, et al. Lack of functional erythropoietin receptors of cancer cell lines. Int J Cancer 2008;122:1005-11.
95. Leyland-Jones B. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003;4:459-60.
96. Leyland-Jones B, Mahmud S. Erythropoietin to treat anaemia in patients with head and neck cancer. Lancet 2004;363:80.
97. Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005;23:5960-72.
98. Littlewood TJ. Response to "Warning flags for erythropoiesis- stimulating agents and cancer-associated anemia". Oncologist 2007;12:1031-4.
99. Littlewood TJ, Bajetta E, Nortier JW, et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865-74.
100. Liu WM, Powles T, Shamash J, et al. Effect of haemopoietic growth factors on cancer cell lines and their role in chemosensitivity. Oncogene 2004;23:981-90.
101. Longmore GD. Do cancer cells express functional erythropoietin receptors? N Engl J Med 2007;356:2447.
102. Lövey J, Bereczky B, Gilly R, et al. Recombinant human erythropoietin alpha improves the efficacy of radiotherapy of a human tumor xenograft, affecting tumor cells and microvessels. Strahlenther Onkol 2008;184:1-7.
103. Lövey J, Kenessey I, Rásó E, et al. Human recombinant erythropoietin-α increases the efficacy of irradiation in preclinical model. Magyar Onkol 2007;51:53-61.
104. Lubin NLC. Transfusion safety: where are we today? Ann NY Acad Sci 2005;1054:325-41.
105. Ludwig H. rHuEPO and treatment outcomes: The preclinical experience. Oncologist 2004;9:48-54.
106. Ludwig H, Crawford J, Österborg A, et al. Patient-level integrated analysis of data from 6 randomized, double-blind, placebo-controlled trials of darbepoetin alfa (DA) in patients (pts) with chemotherapy-induced anemia (CIA). Eur J Cancer 2007;142:Suppl 5:Abstract 1104.
107. Ludwig H, Sundal E, Pecherstorfer M, et al. Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy. Cancer 1995;76:2319-29.
108. Machtay M, Pajak TF, Suntharalingam M, et al. Definitive radiotherapy ± erythropoietin for squamous cell carcinoma of the head and neck: preliminary report of RTOG 99-03. Int J Radiat Oncol Biol Phys 2004;60:Suppl 1:S132.
109. Machtay M, Pajak TF, Suntharalingam M, et al. Radiotherapy with or without erythropoietin for anemic patients with head and neck cancer: a randomized trial of the radiation therapy oncology group (RTOG 99-03). Int J Radiat Oncol Biol Phys 2007;69:1008-17.
110. Magagnin MG, Sergeant K, van den Beucken T, et al. Proteomic analysis of gene expression following hypoxia and reoxygenation reveals proteins involved in the recovery from endoplasmic reticulum and oxidative stress. Radiother Oncol 2007;83:340-5.
111. McBroom JW, Acs G, Rose GS, et al. Erythropoietin receptor function and expression in epithelial ovarian carcinoma. Gynecol Oncol 2005;99:571-7.
112. Mercuriali F, Inghilleri G. Red blood cell transfusion, risks and limitations. In: Nowrousian MR, ed. Recombinant human erythropoietin (rhEPO) in clinical oncology. Wien-New York: Springer, 2002:185-201.
113. Miceli MH, Dong L, Grazziutti ML, et al. Iron overload is a major risk factor for severe infection after autologous stem cell transplantation: a study of 367 myeloma patients. Bone Marrow Transplant 2006;37:857-64.
114. Mittelman M, Neumann D, Peled A, et al. Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models. Proc Natl Acad Sci USA 2001;98:5181-6.
115. Moebus V, Lueck H, Thomssen C, et al. The impact of epoetin-alpha on anemia, red blood cell (RBC) transfusions, and survival in breast cancer patients (pts) treated with dose-dense sequential chemotherapy: mature results of an AGO phase III study (ETC trial). J Clin Oncol 2007;25:Suppl:569.
116. Mohyeldin A, Lu H, Dalgard C, et al. Erythropoietin signaling promotes invasiveness of human head and neck squamous cell carcinoma. Neoplasia 2005;7:537-43.
117. NCCN. Cancer- and treatment-related anemia. Fort Washington, PA, USA, NCCN, 2007 ( http://www.nccn.org/professionals/physician:gls/PDF/anemia.pdf).
118. Ning S, Hartley C, Molinex G, et al. Darbepoetin alfa potentiates the efficacy of radiation therapy in mice with corrected or uncorrected anemia. Cancer Res 2005;65:284-90.
119. Nowrousian MR. Pathophysiology of anaemia in cancer. In: Bokemeyer C, Ludwig H, eds. Anaemia in cancer, 2nd edn. Edinburgh: Elsevier, 2005:25-45.
120. Nowrousian MR. Addendum 1. In: Nowrousian MR, ed. Recombinant human erythropoietin (rhEPO) in clinical oncology - scientific and clinical aspects of anemia in cancer, 2nd edn. Wien-New York: Springer, 2008:851.
121. Nowrousian MR. rhEPO in anemic patients with solid tumors and chemotherapy - efficacy and safety. In: Nowrousian MR, ed. Recombinant human erythropoietin (rhEPO) in clinical oncology - scientific and clinical aspects of anemia in cancer, 2nd edn. Wien-New York: Springer, 2008:449-508.
122. Nowrousian MR, Kasper C, Oberhoff C, et al. Pathophysiology of cancer related anemia. In: Smyth JF, Boogaerts MA, Ehmer BRM, eds. rhErythropoietin in cancer supportive treatment. New York-Basel-Hong Kong: Dekker, 1996:13-34.
123. Offner PJ. Age of blood: does it make a difference? Crit Care 2004;8:Suppl 2:S24-6.
124. Österborg A. Recombinant human erythropoietin (rHuEPO) therapy in patients with cancer-related anaemia: what have we learned? Med Oncol 1998;15:Suppl 1:S47-9.
125. Österborg A, Aapro M, Cornes P, et al. Preclinical studies of erythropoietin receptor expression in tumour cells: impact on clinical use of erythropoietic proteins to correct cancer-related anaemia. Eur J Cancer 2007;43:510-9.
126. Österborg A, Boogaerts MA, Cimino R, et al. Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma - a randomized multicenter study. The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin's Lymphoma. Blood 1996;87:2675-82.
127. Österborg A, Brandberg Y, Hedenus M. Impact of epoetin-α on survival of patients with lymphoproliferative malignancies: long-term follow-up of a large randomized study. Br J Haematol 2005;129:206-9.
128. Overgaard J, Hoff C, Sand Hansen H, et al. Study of the importance of novel erythropoiesis stimulating protein (Aranesp) for the effect of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC) - the Danish Head and Neck Cancer Group DAHANCA 10 randomized trial. Eur J Cancer Suppl 2007;5:7.
129. Palumbo C, Battisti S, Carbone D, et al. Recombinant erythropoietin differently affects proliferation of mesothelioma cells but not sensitivity to cisplatin and pemetrexed. Cancer Chemother Pharmacol 2008:in press.
130. Pape A. Alternatives to allogeneic blood transfusions. Best Pract Res Clin Anaesthesiol 2007;21:221-39.
131. Pirker R, Ramlau R, Schuette W, et al. A phase 3 randomized, double-blind, placebo-controlled study of patients with previously untreated extensive-stage small cell lung cancer (SCLC) treated with platinum plus etoposide chemotherapy with or without darbepoetin alfa. J Thorac Oncol 2007;2:Suppl 4:S433, Abstract PD6-3-6.
132. Prosnitz RG, Yao B, Farrell CL, et al. Pretreatment anemia is correlated with the reduced effectiveness of radiation and concurrent chemotherapy in advanced head and neck cancer. Int J Radiat Oncol Biol Phys 2005;61:1087-95.
133. Raghavan M, Marik PE. Anemia, allogenic blood transfusion, and immunomodulation in the critically ill. Chest 2005;127:295-307.
134. Reed N, Chan S, Hayward C, et al. Impact of epoetin beta on the survival of anemic patients with ovarian cancer receiving platinum-based chemotherapy. J Clin Oncol 2005;23:Suppl:479s, Abstract 5102.
135. Rizzo JD, Somerfield MR, Hagerty KL, et al. American Society of Clinical Oncology/American Society of Hematology 2007. Clinical practice guideline update on the use of epoetin and darbepoetin. J Clin Oncol 2007;25:1-17.
136. Rofstad EK, Galappathi K, Mathiesen B, et al. Fluctuating and diffusion-limited hypoxia in hypoxia-induced metastasis. Clin Cancer Res 2007;13:1971-8.
137. Rohrer Bley C, Ohlert S, Roos M, et al. Influence of pretreatment polarographically measured oxygenation levels in spontaneous canine tumors treated with radiation therapy. Strahlenther Onkol 2006;182:518-24.
138. Rosen FR, Haraf DJ, Kies MS, et al. Multicenter randomized phase II study of paclitaxel (1 hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer. Clin Cancer Res 2003;9:1689-97.
139. Ross SD, Allen JE, Henry DH, et al. Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature. Clin Ther 2006;28:801-31.
140. Said HM, Hagemann C, Stojic J, et al. Expression der Hypoxie-assoziierten Gene OPN, CA9, VEGF und EPO in humanen astrocytären Hirntumoren in vivo und in vitro. Strahlenther Onkol 2007;183:Sondernr 1:62.
141. Sanders RP, Geiger TL, Heddle N, et al. A revised classification scheme for acute transfusion reactions. Transfusion 2007;47:621-8.
142. Sawabe Y, Takiguchi Y, Kikuno K, et al. Changes in levels of serum erythropoietin, serum iron and unsaturated iron binding capacity during chemotherapy for lung cancer. Jap J Clin Oncol 1998;28:182-6.
143. Shannon AM, Bouchier-Hayes DJ, Condron CM, et al. Correction of anaemia through the use of darbepoetin alfa improves chemotherapeutic outcome in a murine model of Lewis lung carcinoma. Br J Cancer 2005;93:224-32.
144. Sigounas G, Sallah S, Sigounas VY. Erythropoietin modulates the anticancer activity of chemotherapeutic drugs in a murine lung cancer model. Cancer Lett 2004;214:171-9.
145. Silver DF, Piver MS. Effects of recombinant human erythropoietin on the antitumor effect of cisplatin in SCID mice bearing human ovarian cancer: a possible oxygen effect. Gynecol Oncol 1999;73:280-4.
146. Sinclair AM, Todd MD, Forsythe K, et al. Expression and function of erythropoietin receptors in tumors. Cancer 2007;110:477-88.
147. Smith RE, Aapro MS, Ludwig H, et al. Darbepoetin alfa for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol 2008:in press.
148. Solar P, Feldman L, Jeong JY, et al. Erythropoietin treatment of human ovarian cancer cells results in enhanced signaling and a paclitaxel-resistant phenotype. Int J Cancer 2008;122:281-8.
149. Spiess BD. Risks of transfusion: outcome focus. Transfusion 2004;44 (Suppl 12):4S-14S.
150. Staab A, Löffler J, Said HM, et al. Hypoxie, Glukosestoffwechsel und HIF: ein komplexes Wechselspiel. Strahlenther Onkol 2007;183:Sondernr 1:64.
151. Steensma DP, Loprinzi CL. Erythropoietin use in cancer patients: a matter of life and death? J Clin Oncol 2005;23:5865-8.
152. Strauss HG, Haensgen G, Dunst J, et al. Effects of anaemia correction with epoetin beta in patients receiving radiochemotherapy for advanced cervical cancer. Int J Gynecol Cancer 2008:in press.
153. Stüben G, Pöttgen C, Knuhmann K, et al. Erythropoietin restores the anemia-induced reduction in radiosensitivity of experimental human tumors in nude mice. Int J Radiat Oncol Biol Phys 2003;55:1358-62.
154. Stüben G, Thews O, Pöttgen C, et al. Recombinant human erythropoietin increases the radiosensitivity of xenografted human tumours in anaemic nude mice. J Cancer Res Clin Oncol 2001;127:346-50.
155. Stüben G, Thews O, Pöttgen C, et al. Impact of anemia prevention by recombinant human erythropoietin on the sensitivity of xenografted glioblastomas to fractionated irradiation. Strahlenther Onkol 2003;179:620-25.
156. Thews O, Kelleher DK, Vaupel P. Erythropoietin restores the anemia-induced reduction in cyclophosphamide cytotoxicity in rat tumors. Cancer Res 2001;61:1358-61.
157. Thews O, Koenig R, Kelleher DK, et al. Enhanced radiosensitivity in experimental tumours following erythropoietin treatment of chemotherapyinduced anaemia. Br J Cancer 1998;78:752-6.
158. Throuvalas N, Antonadou D, Lavey R, et al. Final results of a randomized phase II study evaluating the role of erythropoietin during radiochemotherapy for pelvic tumors. Int J Radiat Oncol Biol Phys 2004;60:Suppl 1:S300.
159. Tóvári J, Gilly R, Rásó E, et al. Recombinant human erythropoietin ? targets intratumoral blood vessels, improving chemotherapy in human xenograft models. Cancer Res 2005;65:7186-93.
160. Tullai J, Chitikila C, Gechtman Z, et al. Erythropoietin did not activate the JAK/STAT or the ERK 1/2 pathway in human colorectal cell line, HT-29. Blood 2004;104:4221.
161. Uchida M, Watanabe T, Kunitama M, et al. Erythropoietin overcomes imatinib-induced apoptosis and induces erythroid differentiation in TF-1/ bcr-abl cells. Stem Cells 2004;22:609-16.
162. Van Belle SJ-P, Cocquyt V. Impact of haemoglobin levels on the outcome of cancers treated with chemotherapy. Crit Rev Oncol Hematol 2003;47:1-11.
163. Vansteenkiste J, Pirker R, Massuti B, et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002;94:1211-20.
164. Vaupel P, Dunst J, Engert A, et al. Effects of recombinant human erythropoietin (rHuEPO) on tumor control in patients with cancer-induced anemia. Onkologie 2005;28:216-21.
165. Vaupel P, Mayer A. Erythropoietin to treat anaemia in patients with head and neck cancer. Lancet 2004;363:992.
166. Vaupel P, Mayer A, Höckel M. Impact of hemoglobin levels on tumor oxygenation: the higher, the better? Strahlenther Onkol 2006;182:63-71.
167. Vaupel P, Thews O, Mayer A, et al. Oxygenation status of gynecological tumors: what is the optimal hemoglobin level? Strahlenther Onkol 2002;178:727-31.
168. Weinberg ED. Iron therapy and cancer. Kidney Int Suppl 1999;69:S131-4.
169. Weinmann M, Jendrossek V, Güner D, et al. Cyclic exposure to hypoxia and reoxygenation selects for tumor cells with defects in mitochondrial apoptotic pathways. FASEB J 2004;18:1906-8.
170. Westenfelder C, Baranowski RL. Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidney Int 2000;58:647-57.
171. Westphal G, Niederberger E, Blum C, et al. Erythropietin and G-CSF receptors in human tumor cells: expression and aspects regarding functionality. Tumori 2002;88:150-9.
172. Wright JR, Ung YC, Julian JA, et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 2007;25:1027-32.